Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Gyongyos – page 3

223 clinical trials in Gyongyos, Hungary across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gyongyos at a glance
223
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

223 trials in Gyongyos

Open in trial search

Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Eltrekibart
  • Sponsor:Eli Lilly & Co.

Study comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Crohn's disease

Recruiting

Study on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:MORF-057
  • Sponsor:Morphic Therapeutic Inc.

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Cardiac failure

Recruiting

Study on the Effects and Safety of Finerenone for Patients with Heart Failure Who Cannot Use Steroidal Mineralocorticoid Receptor Antagonists

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Cardiac failure

Recruiting

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

First-line treatment of metastatic non‑small cell lung cancer with high PD‑L1 expression: ivonescimab versus pembrolizumab

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Ivonescimab
  • Sponsor:Summit Therapeutics Inc.

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AstraZeneca AB

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Gyongyos

What the registry says about research in the country

01 Respiratory Diseases

Research focusing on innovative treatments for non-small cell lung cancer (NSCLC) and chronic respiratory conditions, with multiple trials evaluating new immunotherapy combinations and targeted therapies.

  • Advanced NSCLC Treatment Studies
  • COPD Management Research
  • Idiopathic Pulmonary Fibrosis Studies

Several trials are exploring combination therapies to improve patient outcomes in advanced stages of lung cancer.

02 Autoimmune Conditions

Comprehensive studies on inflammatory and autoimmune disorders, including psoriasis and inflammatory bowel diseases, testing novel therapeutic approaches.

  • Plaque Psoriasis Treatments
  • Ulcerative Colitis Therapies
  • Crohn's Disease Management

Multiple trials are evaluating new biological therapies for moderate to severe cases of these conditions.

03 Cardiovascular Research

Innovative studies targeting heart failure prevention and cardiovascular disease management, with a focus on reducing major adverse cardiac events.

  • Heart Failure Prevention
  • Atherosclerotic Disease
  • Cardiovascular Risk Management

Research includes novel therapeutic combinations and preventive strategies for high-risk patients.

04 Neurological Disorders

Clinical research focusing on Alzheimer's Disease and associated conditions, particularly investigating treatments for psychosis symptoms.

  • Alzheimer's-Related Psychosis
  • Cognitive Function Studies

Trials are evaluating new therapeutic approaches for managing neuropsychiatric symptoms.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.